Ozempic maker Novo Nordisk (NVO) is closing its cell therapy division as part of a major restructuring drive initiated under the company’s new CEO, Mike Doustdar, Bloomberg News reported on Thursday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback